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Background: Chronotropic incompetence (CI) is a marker of poor prognosis in patients with
COPD. Treatments that improve pulmonary function and exercise capacity may affect CI.
Objectives are to evaluate CI before and after lung volume reduction surgery (LVRS) and deter-
mine if changes in CI are associated with changes in pulmonary function and exercise capacity.
Methods: We performed a retrospective review of 75 patients who underwent LVRS and who
had complete cardiopulmonary exercise testing and concurrent pulmonary function tests
two months before and about 6 months after surgery. Additionally we evaluated 28 control
patients that were randomized to medical treatment as part of the National Emphysema
Treatment Trial at our center. We studied CI using the percent of predicted heart rate reser-
veZ (heart rate peak heart rate rest)/((208 0.7 age) heart rate rest) 100, before
and after surgery and compared it to the control group.
Results: Mean percent of predicted heart rate reserve improved from 41% to 50% (p-value
<0.001) after LVRS, while the control group did not change. The mean forced vital capacity
and expiratory volume in 1 s, peak oxygen consumption, carbon dioxide production, ventila-
tion, tidal volume and maximal workload all improved in the surgery group, while the controls
did not improve.305 9416; fax: þ1 212 342 1855.
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1390 H.F. Armstrong et al.Conclusions: CI improves after LVRS in a population of patients with COPD. CI improvements
are associated with the increases in pulmonary function and exercise capacity. This improve-
ment is seen in a domain of known cardiopulmonary impairment prior to surgery that improves
as a positive response to the therapy of LVRS.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is now the
third leading cause of death in the United States,1 and lung
volume reduction surgery (LVRS) has been shown to be an
effective treatment for a subset of patients with severe
emphysema. In appropriately selected patients, LVRS can
decrease morbidity, mortality2,3 and dyspnea, while
improving exercise performance,4,5 endurance,6 pulmonary
function,4 and quality of life.5 While many of these benefits
likely represent improvements in pulmonary mechanics,7
improvements in cardiovascular function have also been
postulated to play a role.8
Recently, in a population-based study of normal patients
and those with mild COPD, Barr et al. showed that the
degree of airflow obstruction is significantly associated with
reduced left ventricular end-diastolic volume, stroke
volume and cardiac output.9 Additionally, it has been
shown that hyperinflation is significantly associated with
impaired left ventricular filling and right ventricular
dysfunction and that the impaired left ventricular filling is
independently associated with decreased exercise toler-
ance.10,11 As these studies imply, the degree to which
impaired cardiac function can be augmented by reducing
hyperinflation may have implications in patient care.10
Chronotropic incompetence (CI), or an attenuated heart
rate (HR) response to exercise, has the highest prevalence
among individuals with the most impaired exercise
capacity12 but CI is also seen in healthy obese subjects,
healthy smokers,13, 14 and patients with COPD.14e16 Treat-
ments that improve pulmonary function, such as LVRS, may
have a secondary benefit on improving cardiac function and
thus also improving CI. To address this uncertainty, the
current study was designed using cardiopulmonary exercise
testing (CPET) parameters to investigate the effect of LVRS
on CI in a group of patients with emphysema. To evaluate
our hypothesis we had a specific aim to evaluate the effect
of LVRS on CI compared to controls that had no surgery but
continued maximal medical care.Materials and methods
Patients
The Institutional Review Board of the New York Presbyte-
rian, Columbia University Medical Center approved this
study. A retrospective chart review was performed on all
patients who had undergone LVRS at Columbia University
Medical Center from January 1998 to October 2009.
Patients who had CPET and pulmonary function tests (PFT)
within 2 months before LVRS and repeat testingapproximately 6 months after were included. PFTs
concurrent with CPET were chosen. The patients under-
went rehabilitation, performed the first CPET 2 months
before LVRS, underwent post-surgery rehabilitation and
then performed the second CPET six months after LVRS.
In order to rule out the possible effects of the intensive
pre- and post-LVRS pulmonary rehabilitation given to the
patients, we analyzed the National Emphysema Treatment
Trial (NETT) patients that were randomized to medical
treatment (which included pulmonary rehabilitation) at our
center.
Exercise and pulmonary function testing
CPET was performed on an electronically braked cycle
ergometer (Ergometrics 800, SensorMedics Inc., Yorba
Linda, CA) with a Viasys Sensormedics Encore metabolic
cart (Viasys Corporation, Loma Linda, CA); prior to 2005
a Vmax 229 series workstation (SensorMedics Inc., Yorba
Linda, CA) was used. Continuous 12-lead telemetry was
monitored via CardioSoft electrocardiogram software (GE/
CardioSoft, Houston, TX); prior to 2005 a model Max-1
electrocardiogram was used (Marquette Medical Systems;
Milwaukee, WI). Oxygen saturation was recorded with
a N595 pulse oximeter (Nellcor, Boulder, CO); prior to 2005
a Sensormedics Sat-Trak (SensorMedics Inc., Yorba Linda,
CA) was used. All patients were tested on 30% fractional
inspired oxygen via mouthpiece both before and after LVRS.
The exercise protocol was ramping and followed the
protocol used in the NETT3 and American Thoracic Society
guidelines.17,18 The same ramp was used at baseline and at
the 6 month CPET. CPET variables were collected breath by
breath and included rate of carbon dioxide production
(VCO2), maximal workload (peak watts), oxygen consump-
tion by weight (VO2 in mL/kg/min), percent of predicted
oxygen consumption attained (VO2 %), minute ventilation
(VE), tidal volume (Vt), respiratory rate (RR), end-tidal CO2
pressure (PetCO2), HR at baseline (HRrest), heart rate at
peak exercise (HRmax), systolic blood pressure at baseline
and at peak exercise (SBPrest and SBPmax) and diastolic
blood pressure at baseline and at peak exercise (DBPrest and
DBPmax). All PFTs were performed according to the NETT
protocol.3 This included the forced vital capacity (FVC),
forced expiratory volume in 1 s (FEV1), total lung capacity
(TLC), and residual volume (RV). Percent of predicted PFTs
was calculated for males and females as described in prior
publications.19e21
Age predicted peak HR was calculated using
208 0.7 age.22 CI was assessed using the percent of
predicted heart rate reserve (%HRR)Z(HRmax HRrest)/
((age predicted HR) HRrest) 100.23 A %HRR below 80% in
the absence of beta-blocker therapy is considered
Table 1 Comparison of pulmonary function before and
after LVRS.
nZ 75 Before LVRS After LVRS p-Value
FEV1 0.69 0.17 0.97 0.34 <0.001
FEV1 % 26 7% 37 14% <0.001
FVC 2.13 0.67 2.74 0.73 <0.001
FVC % 61 17% 80 18% <0.001
TLC 7.08 1.44 6.36 1.38 <0.001
TLC % 127 13% 114 15% <0.001
RV 4.77 1.13 3.47 1.08 <0.001
RV % 229 46% 166 47% <0.001
RV/TLC 0.67 0.08 0.54 0.10 <0.001
FEV1 e forced expiratory volume in one second; FVC e forced
vital capacity; TLC- total lung capacity; RV e residual volume;
and RV/TLC e ratio of residual volume to total lung capacity.
% e percent of predicted.
CI and LVRS 1391abnormal and shown to be a predictor of mortality.16,23 PFT
and CPET values before LVRS were compared to the values
after to determine the effects of LVRS on pulmonary
function, HR and peak exercise capacity.
Statistics
Data were analyzed with SPSS version 18 (SPSS, Chicago,
IL). The distribution of the variables was assessed using the
KolmogoroveSmirnov test. Variables that were normally
distributed are presented as mean standard deviation.
Variables that deviated from normal are presented as
median and interquartile range (IQR) (25%, 75%). Contin-
uous variables were analyzed with paired-samples t-test.
Analysis of group differences for non-normally distributed
variables was analyzed with the Wilcoxon matched-pair
signed rank test. Pearson’s correlations were used to
determine the associations between variables. Indepen-
dent samples t-test was used to assess differences between
those included and not and between the control and
surgery groups. Statistical significance was set at p 0.005
since multiple comparisons were performed.
Results
Patients
Of 125 patients who had undergone LVRS between 1998 and
2009, 82 patients had PFT and CPET data before and after
LVRS. The median time between the first CPET and surgery
was 39 (15, 67) days while the median time between
surgery and the second CPET was 195 (176, 220) days.
Despite our usual practice to perform CPET both before and
after surgery to assess function and help guide exercise
programs, there was variability in practice before the NETT
guidelines were established in 2004. Twenty-two patients
had no CPET before LVRS, 17 patients had no CPET after
LVRS due to loss of follow up and 4 patients died within 6
months of surgery. Three additional patients were excluded
because the CPET before LVRS was done on room air instead
of supplemental oxygen, and 4 had ischemic heart
disease, leaving 75 (57% female, 63 7 years old, BMI of
24 5 kg/m2) patients available for analysis. Twenty-five of
these cases were performed as part of the NETT. There
were no differences in terms of gender or age between
those included and not included (data not shown). Medi-
cations were not significantly different between patients
before and after surgery. Specifically, with regard to car-
dioactive medications, all patients were on beta agonist
before and after surgery, with none on beta blockade, 97%
of patients were on anticholinergic medications before and
after surgery, 24% were on calcium channel blocker before
surgery, only one additional patient started calcium
channel blocker for peri-operative tachycardia, and 6%
were on digitalis before and after surgery.
All patients were chronic ex-smokers who were
confirmed abstinent from smoking for at least 6 months
prior to and post-surgery. All patients had an electrocar-
diogram at the time of CPET and were in sinus rhythm. None
had active ischemic heart disease by screening from
dobutamine stress echocardiogram or thallium testing andcardiac catheterization for those patients with any suspi-
cious changes on the dobutamine testing. Left ventricular
ejection fraction (>45%) and absence of significant valvular
disease was confirmed by review of echocardiogram or left
heart catheterization closest to the time of the first CPET.
The PFT parameters of the LVRS group before and after
surgery can be seen in Table 1. All PFT variables changed
significantly. The mean FEV1 % and FVC % increased while
the TLC %, RV % and RV/TLC ratio decreased following LVRS.
Resting parameters
Slightly above our significance level but notable, the mean
HRrest decreased from 89 bpm to 85 bpm (pZ 0.008) and
the SBPrest decreased from 131 mmHg to 127 mmHg
(pZ 0.007) after LVRS (Table 2).
Exercise parameters
The CPET variables that significantly improved following
LVRS can be seen in Table 2. The %HRR significantly
improved from 41% to 50% after LVRS (Fig. 1), attributable
to the decrease in HRrest and increase in HRmax. Before
LVRS, only one patient had a normal %HRR, after LVRS,
three patients had a normal %HRR. The PetCO2 significantly
decreased with exercise, demonstrating decreased CO2
retention. Slightly above significance but notable, the
mean O2 pulse peak (pZ 0.007) was higher, suggesting an
improvement in stroke volume after LVRS.
Since the surgery group significantly increased their
exercise capacity, we looked at %HRR during comparable
workloads (iso-workload) before and after LVRS (Table 3).
Notably, the PetCO2, SBP and DBP all decreased while the
Vt increased when matching for wattage. The HR trended
to decrease from 118 bpm to 114 bpm (pZ 0.015).
Correlations
Additionally we looked at the Pearson’s correlation for
percent change of each variable with change in %HRR. For
example, the percent change in watts would be calculated
as: (after LVRS watts before LVRS watts)/before LVRS
watts 100. The peak VO2, VE, and VCO2 all significantly
correlated with the change in %HRR (rZ 0.474, 0.498, and
0.506, respectively; p< 0.001 all). Just above significance,
Table 2 Comparison of exercise data before and after LVRS.
Before LVRS After LVRS p-Value
Resting VO2 (mL/kg/min) 5.14 1.51 4.90 1.48 0.372
Peak VO2 (mL/kg/min) 13.61 3.39 15.00 3.82 <0.001
Peak VO2 % predicted 47 14% 53 16% <0.001
Maximal workload (Watts) 37 16 46 18 <0.001
Peak VCO2 (mL/kg/min) 11.51 3.24 13.92 4.26 <0.001
PetCO2 (mmHg) 42.4 6.5 40.0 6.0 <0.001
Peak SpO2 (%) 96% (94%, 97%) 97% (95%, 98%) 0.067
a
Peak VE (L/min) 23.8 (19.1, 28.8) 28.0 (22.9, 34.1) <0.001a
Peak Vt (L) 0.89 0.27 1.15 0.35 <0.001
Peak RR (breaths/min) 29 7 27 6 0.005
Breathing Reserve 11 19% 20 17% 0.001
HRrest (beats/min) 89 12 85 12 0.008
HRmax (beats/min) 119 15 124 16 0.002
%HRR 41 17% 50 18% <0.001
Resting O2 pulse (mL/beat) 3.78 0.92 3.93 1.01 0.219
Peak O2 pulse (mL/beat) 7.63 2.48 8.16 2.57 0.007
SBPrest (mmHg) 131 16 127 14 0.007
SBPmax (mmHg) 182 17 182 17 0.882
DBPrest (mmHg) 76 7 74 8 0.085
DBPmax (mmHg) 91 9 90 9 0.142
VO2 e volume of oxygen consumed; VO2 % e percent of predicted volume of oxygen consumed; VCO2 e rate of carbon dioxide
production; PetCO2 e pressure of end-tidal carbon dioxide; SpO2 e arterial saturation; VE e minute ventilation; Vt e tidal volume; RR e
respiratory rate; HRrest e heart rate at baseline; HRmax e heart rate at peak exercise; %HRR e percent of predicted heart rate reserve
calculated as (HRmax HRrest)/((220 age) HRrest) 100; O2 pulse e mL of oxygen per heartbeat; SBPrest e systolic blood pressure at
baseline; SBPmax e systolic blood pressure at peak exercise; DBPrest e diastolic blood pressure at baseline; and DBPmax e diastolic blood
pressure at peak exercise
74 patients have breathing reserve and SpO2 data available.
72 patients have PetCO2 and VCO2 data available.
71 patients have Vt, RR, SBPmax and DBPmax data available.
73 patients have SBPrest and DBPrest.
a Wilcoxon signed ranks test used.
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(rZ 0.308, pZ 0.007). Although not in our significance
range, Vt and FEV1 correlated at rZ 0.232 and rZ 0.224
(pZ 0.051 and pZ 0.053, respectively).Figure 1 Boxplot shows that the %HRR significantly improved
from a median (IQR) of 40% (30e52%) to 48% (34e64%)
(p< 0.001).Control group
Our control group consisted of 28 patients (39% female,
66 6 years old, BMI of 24.2 3.3 kg/m2) from the NETT
that had similar severity of disease and were randomized to
medical treatment and pulmonary rehabilitation at our
center. All controls underwent the same screening (sinus
rhythm, ischemic heart disease, etc.) as the surgery group.
Medications were not significantly different between
controls at baseline and second test. Specifically, with
regard to cardioactive medications, all controls were on
inhaled beta agonist and anticholinergic medications for
both tests, with none on beta blockade or calcium channel
blockade, and 12% were on digitalis for both tests. A
comparison of the LVRS and control group is shown in Table
4. There were no significant differences between the
surgery and control groups in terms of age, gender, BMI or
PFT variables. There was a difference in the peak VO2 %
predicted and significant difference in breathing reserve
with the LVRS group having a lower VO2 and a higher
breathing reserve.
At the second CPET and PFT, the TLC % and RV %
significantly decreased as seen in Table 5. However, there
were no significant changes in any of the exercise capacity
variables or iso-workload variables (data not shown). CI as
measured by %HRR also did not change (first CPET %HRR:
Table 3 Comparison of before and after lvRS Iso-
workload.
Before LVRS After LVRS p-Value
Watts 35 15 35 16
VO2 (mL/kg/min) 13.25 3.39 12.72 3.69 0.091
VCO2 (mL/kg/min) 11.18 3.22 11.47 3.50 0.304
VE (L/min) 24.3 7.6 25.7 7.7 0.013
Vt (L) 0.90 0.27 1.10 0.35 <0.001
SBP (mmHg) 180 18 170 20 0.005
DBP (mmHg) 90 9 85 9 0.001
PetCO2 (mmHg) 42.1 6.3 39.0 6.2 0.002
HR (beats/minute) 118 15 114 18 0.015
%HRR 40 18% 37 14% 0.154
VO2 e volume of oxygen consumed; VCO2 e rate of carbon
dioxide production; VE e minute ventilation; Vt e tidal volume;
SBP e systolic blood pressure; DBP e diastolic blood pressure;
PetCO2 e pressure of end-tidal carbon dioxide; HR e heart rate
at iso-workload; and %HRR e percent of predicted heart rate
reserve at iso-workload.
72 patients have VCO2, Vt and PetCO2 data available.
51 patients have SBP and DBP data available.
Table 4 Comparison of baseline data for LVRS and
controls.
LVRS nZ 75 Controls nZ 28 p-Value
Age (years) 63 7 66 7 0.038
BMI kg/m2 23.9 4.0 24.2 3.3 0.737
Gender (M/F) 32/43 17/11 0.103
FEV1 % 26 7% 23 7% 0.110
FVC % 61 17% 57 15% 0.352
TLC % 127 13% 131 15% 0.227
RV % 229 46% 246 59% 0.157
RV/TLC 0.67 0.08 0.69 0.09 0.440
Resting VO2
(mL/kg/min)
5.14 1.51 5.19 0.98 0.833
Peak VO2
(mL/kg/min)
13.61 3.39 15.49 5.17 0.083
Peak VO2 %
predicted
47 14% 56 18% 0.027
Maximal
workload
(Watts)
37 16 38 20 0.849
Peak VCO2
(mL/kg/min)
11.51 3.24 0.208
PetCO2 (mmHg) 42.4 6.5 41.9 7.7 0.969
Peak SpO2 (%) 96 3% 95 3% 0.054
Peak VE
(L/min)
24.8 7.6 28.7 10.2 0.073
Peak Vt (L) 0.89 0.27 0.97 0.32 0.248
Peak RR
(breaths/min)
29 7 30 8 0.384
Breathing Reserve 11 19% 5% 23% 0.002
HRrest (beats/min) 89 12 91 16 0.407
HRmax (beats/min) 119 15 122 20 0.500
%HRR 41 17% 45 22% 0.360
Resting O2 pulse
(mL/beat)
3.78 0.92 4.12 1.39 0.244
Peak O2 pulse
(mL/beat)
7.63 2.48 9.19 4.06 0.065
SBPrest (mmHg) 131 13 130 10 0.520
SBPmax (mmHg) 182 17 187 14 0.187
DBPrest (mmHg) 76 7 74 6 0.095
DBPmax (mmHg) 91 9 94 6 0.053
FEV1 % e percent of predicted forced expiratory volume in one
second; FVC % e percent of predicted forced vital capacity; TLC
% e percent of predicted total lung capacity; RV % e percent of
predicted residual volume; RV/TLC e ratio of residual volume
to total lung capacity. VO2 e volume of oxygen consumed; VO2 %
e percent of predicted volume of oxygen consumed; VCO2 e
rate of carbon dioxide production; PetCO2 e pressure of end-
tidal carbon dioxide; SpO2 e arterial saturation; VE e minute
ventilation; Vt e tidal volume; RR e respiratory rate; HRrest e
heart rate at baseline; HRmax e heart rate at peak exercise; %
HRR e percent of predicted heart rate reserve calculated as
(HRmax HRrest)/((220 age) HRrest) 100; O2 pulse e mL of
oxygen per heartbeat; SBPrest e systolic blood pressure at
baseline; SBPmax e systolic blood pressure at peak exercise;
DBPrest e diastolic blood pressure at baseline; and DBPmax e
diastolic blood pressure at peak exercise.
74 patients have breathing reserve and SpO2 data available.
72 patients have PetCO2 and VCO2 data available.
71 patients have Vt, RR, SBPmax and DBPmax data available.
73 patients have SBPrest and DBPrest.
CI and LVRS 139345 22%, second CPET %HRR: 41 18%, pZ 0.252). In the
control group, during the first CPET, three patients had
a normal %HRR and on the second CPET none of the patients
had a normal %HRR.
Discussion
The main finding of this study is that LVRS improved CI, as
measured by %HRR, in a group of patients with severe
emphysema compared to similar control patients. In order
to exclude the possible effects of pre- and post-LVRS
pulmonary rehabilitation, the control group was selected
from patients that were randomized to medical therapy
from the NETT at our center. Before undergoing LVRS, the
entire cohort (both patients and controls) had a mean %HRR
of approximately 40e45%. After LVRS, the patients’ %HRR
significantly improved from 41% to 50%. In comparison,
%HRR did not improve for the control group that underwent
pulmonary rehabilitation and maximal medical care. Addi-
tionally, the mean PFT and CPET variables for the 75
patients analyzed also improved, which is in agreement
with prior studies.3,5,24e27
While other studies have looked at CI in patients with
COPD,14e16 to the best of our knowledge, this is the first to
look at the effect of LVRS on CI. The cause of this
improvement may include improved exercise capacity but
may also have a component of alteration of autonomic tone
due to improved lung function. Patients with COPD can
demonstrate a number of sympathetic nervous system
abnormalities that are thought to be related to alterations
of ventilatory mechanics with subsequent cardiopulmonary
changes, including increased pulmonary vascular resis-
tance, increased right ventricular after load, and reduced
right ventricular filling.25,28e30 These abnormalities may
increase sympathetic activity at rest and during exercise,
as there is decreased stroke volume with alterations in
cardiac output and right ventricular ejection
fraction.24,28,31e33 One could speculate that a proportion of
Table 5 Comparison of pulmonary function-control
group.
nZ 28 1st CPET 2nd CPET p-Value
FEV1 % 23 7% 24 7% 0.532
FVC % 57 15% 62 15% 0.088
TLC % 131 15% 125 15% 0.001
RV % 246 59% 228 49% 0.011
RV/TLC 0.69 0.09 0.67 0.09 0.189
FEV1 % e percent of predicted forced expiratory volume in 1 s;
FVC % e percent of predicted forced vital capacity; TLC % e
percent of predicted total lung capacity; RV % e percent of
predicted residual volume; and RV/TLC e ratio of residual
volume to total lung capacity.
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related to decreased sympathetic tone at rest with lower
HRrest and improved HRmax along with changes in cardiac
output, stroke volume, and right ventricular function,24,25
all allowing increased exercise performance. We also
found improvements in PetCO2 after LVRS which may have
improved autonomic tone through decreased central
chemoreceptor stimulation.34,35 Similarly, an alteration of
the pulmonary mechanics after LVRS may also have signif-
icant effects on autonomic modulation.
Another mechanism for the observed improvement in CI
after LVRS may be through the improvement in peak
workload and the improvement in right ventricular func-
tion, shown in prior studies,5,6,8,25 as a result of the
improved ventilatory mechanics. Additionally, the percent
change in peak VO2 and watts correlated with the change in
%HRR, showing that the two changes were associated with
each other. The exercise improvements are likely through
a combination of improved VE, Vt, and breathing reserve
with a reduced RV/TLC ratio (decreased hyperinflation) and
PetCO2 (decreased air trapping).
Additionally, the patients who underwent LVRS also
improved their cardiac function. The HRrest, HRmax and O2
pulse peak all improved. Although higher HRmax may be
explained by an increase in overall exercise capacity, this
cannot be extended to the decrease in HRrest. Jorgensen
et al. documented augmentation in myocardial performance
with increased stroke volume and work index and normali-
zation of left ventricular end-diastolic dimensions and left
ventricular filling after LVRS.8 Although an indirect measure
of stroke volume, we showed an increase in the O2 pulse at
peak exercise with improvement of CI from reduced HRrest
and increased HRmax, giving a significantly higher %HRR
following LVRS. Possible mechanisms of stroke volume may
increase following LVRS due to decreased external
compression (pulmonary tamponade) from reduced hyper-
inflation and an increase in right24,36,37 and left ventricular
filling.8 This effect may contribute to the decrease in HRrest
seen in our study and is supported by the recent study by Barr
et alwith impaired left ventricularfilling in evenearly COPD.9
Evaluation at iso-workloads before and after LVRS
confirmed the improvement in PetCO2, Vt, SBP and DBP.
This is consistent with a lower work effort at a similar
workload after LVRS. Although there were only small
changes in iso-workload HR and %HRR, the demonstration ofreduced SBP and DBP at similar workloads also indicates
a lower work effort after LVRS.
The chief limitation of this study is that it is retrospec-
tive. This did not allow inclusion of all the cardiovascular or
autonomic measurements that would have permitted
better understanding of the underlying cardiac and hemo-
dynamic changes after LVRS that may have been associated
with improved CI. There may be a period bias between our
control and part of our surgery group since our control
group was only part of the NETT but our surgery group
continued to 2009. Additionally, the baseline differences in
VO2 % predicted and breathing reserve between the control
and patient groups are factors in which the two groups are
not comparable. However, despite this, their %HRR at
baseline was still similar. Since coronary artery disease,
which is relatively common in patients undergoing LVRS,38
has been associated with CI, we screened for it with thal-
lium and echo dobutamine studies with follow-up angiog-
raphy in patients with any abnormality and excluded
subjects who had ischemic disease. The strengths of the
study lie with the relatively large number of LVRS patients
and the strong positive improvement in CI, a noninvasive
cardiac measure, indicating that LVRS may have significant
benefits beyond pulmonary improvements. A prospective
analysis of patients undergoing LVRS with more complete
cardiac evaluation may be able to assess if the improve-
ments in CI after LVRS correspond with a decrease in
cardiac events and mortality.
In conclusion, this is the first study to demonstrate
a clear improvement of chronotropic incompetence after
lung volume reduction surgery in emphysematous patients,
associated with a decrease in resting heart rate and an
increase in peak exercise heart rate. The pulmonary reha-
bilitation control group did not see any of these changes.
This study further describes another known domain of
cardiopulmonary impairment prior to surgery that improves
as a positive response to the therapy of LVRS.
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